Adicet Bio, Inc.
Adicet Bio discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Lead product candidate ADI-001 targets CD20 in Phase I trial for autoimmune diseases and lymphoma. Company also developing ADI-270 for renal cell carcinoma and other solid tumors/hematological malignancies. Founded in 2014, based in Boston, MA.
Overview
Strengths
- Price to book ratio (0.35) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.4 |